Metrics
Publication
80
Open Access
6
UN Sustainable Development Goals
Biography
Assoc. Prof. Dr. Murat Özbalak was born in 1984 in
Istanbul. He completed his primary education at F.M.V. Özel Işık Primary
School and his secondary and high school education at Galatasaray High
School. In 2009, he graduated from the English Medical Program at
Istanbul University Cerrahpaşa Faculty of Medicine.
He completed his residency in internal medicine
in 2015 at Istanbul University Cerrahpaşa Faculty of Medicine. In
November 2015, he began his career as a State Service Obligation physician at Batman
Kozluk State Hospital. From April 2017 to June 2018, he worked at Istanbul
Bahçelievler State Hospital.
Between June 2018 and September 2021, he
completed his subspecialty training in hematology at the Department of
Hematology, Istanbul Faculty of Medicine. Subsequently, he served as a
State Service Obligation physician at Ağrı Training and Research Hospital
Hematology Department from October 2021 to September 2022 and at the Hematology
Clinic of Bahçeşehir Çam and Sakura City Hospital from October 2022 to
February 2024.
In June 2023, he was conferred the title of Associate
Professor of Hematology. Since February 2024, he has been serving as a
faculty member in the Department of Hematology at Istanbul Faculty of
Medicine. Additionally, he is pursuing a doctoral degree in the Department
of Immunology at Aziz Sancar Institute of Experimental Medicine.
He is married and he is a congress member of Galatasaray
Sports Club. He is fluent in both English
and French.
In 2023, Assoc. Prof. Dr. Murat Özbalak successfully completed the Lymphoma Masterclass organized by the Turkish Society of Hematology. He specializes in the diagnosis and treatment of lymphoproliferative disorders, Hodgkin lymphoma, and non-Hodgkin lymphoma.
Announcements & Documents
Download File
Education
2018 - Present
2018 - PresentDoctorate
Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Immunology, Turkey
2018 - 2021
2018 - 2021Post Doctorate of Medicine
Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , Turkey
2010 - 2015
2010 - 2015Expertise In Medicine
İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, Turkey
2003 - 2009
2003 - 2009Undergraduate
İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, English Education Program, Turkey
Dissertations
2015
2015Expertise In Medicine
Killer Immunoglobuline Like Receptor gene analysis in Chronic Lymphocytic Leukemia and its relation with autoimmunity
İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine
Foreign Languages
C1 Advanced
C1 AdvancedEnglish
C1 Advanced
C1 AdvancedFrench
A1 Beginner
A1 BeginnerItalian
Certificates, Courses and Trainings
2023
2023Hematoloji Tıpta Uzmanlık Alanında Yeterlilik Belgesi - Hematology Board Certificate
Health&Medicine
Hematoloji Tıpta UzmanHematology Medical Specialty Certification Commissionlık Yeterlilik Komisyonu
2023
2023Lenfoma Ustalık Sınıfı - Lymphoma Masterclass
Health&Medicine
Turkish Society of Hematology - Turkish Hematology Academy Program
2021
2021Hematology Board Exam Certificate
Health&Medicine
European Hematology Association
2021
2021Deney Hayvanları Kullanım Sertificası - Certificate of Competency in Laboratory Animal Use
Health&Medicine
Istanbul University
2014
2014ECFMG Certificate
Health&Medicine
Educational Commission for Foreign Medical Graduates (ECFMG)
Research Areas
Medicine
Internal Medicine Sciences
Internal Diseases
Hematology
Immunology and Rheumatology
Health Sciences
Academic Positions
2018 - 2021
2018 - 2021Specialization Student
Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences
2010 - 2015
2010 - 2015Specialization Student
İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine
Articles
All (46)
SCI-E, SSCI, AHCI (29)
SCI-E, SSCI, AHCI, ESCI (39)
ESCI (10)
Scopus (34)
TRDizin (8)
Other Publications (2)
2025
20251. Kronik Lenfositik Lösemi Hastalarında CXCR5+CD8+ Foliküler Sitotoksik T hücreleri, CD8+ T hücreleri ve NK Hücrelerinde Perforin ve Granzim Seviyeleri
Gelmez M. Y., Öktelik F. B., Özbalak M. M., Yönal Hindilerden İ., Deniz G.
Acta Medica Nicomedia , vol.8, no.3, pp.308-313, 2025 (Peer-Reviewed Journal)
2025
20252. Kronik Lenfositik Lösemi Hastalarında Notch Ekspresyon Seviyeleri: Akan Hücre Ölçer ile Değerlendirilmesi
ÖKTELİK F. B., ÖZBALAK M. M., YÖNAL HİNDİLERDEN İ., DENİZ G., GELMEZ M. Y.
Acta Medica Nicomedia , vol.8, 2025 (Peer-Reviewed Journal)
2025
20253. Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.
Martínez C., Khvedelidze I., Fekom M., Deau Fischer B., Marouf A., Ghesquières H., et al.
Bone marrow transplantation
, 2025 (SCI-Expanded)
2025
20254. The Effect of T-Lymphocyte Subgroups at Diagnosis on The Prognosis of Chronic Lymphocytic Leukemia.
Seyithanoglu D., Sert E., Ozbalak M. M., Mastanzade M., Erdem S., Yenerel M. N.
Acta haematologica
, pp.1-11, 2025 (SCI-Expanded)
2025
20255. Impact of COVID-19 on Hematologic Disorders: Clinical Insights and Challenges
ERDEM S., SERT EKİNCİ S., ÖZBALAK M. M., MASTANZADE M., YÖNAL HİNDİLERDEN İ., YENEREL M. N., et al.
Istanbul Medical Journal , vol.26, 2025 (ESCI)
2025
20256. Can BATF Expression Serve as a Predictive Marker for Treatment Necessity in Chronic Lymphocytic Leukemia?
GELMEZ M. Y., ÇINAR S., ADAY A., Ozcit G., Ozbalak M., Usta T., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, vol.35, no.3, pp.193-201, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
20257. Congenital thrombotic thrombocytopenic purpura and human leukocyte antigen analysis-an amazing clue.
Kıkılı C. İ., Kıvanç D., Şentürk Çiftçi H., Özbalak M. M., Yenerel M. N., Nalçacı M., et al.
Hematology, transfusion and cell therapy
, vol.47, no.1, pp.103746, 2025 (ESCI)
2024
20248. Central nervous system involvement of mantle cell lymphoma: Case report and review of the literature.
Ağargün B. F., Özbalak M. M., Gülseren Ü. A., Yegen G., Beşışık S.
Hematology, transfusion and cell therapy
, vol.46, 2024 (ESCI)
2024
20249. Long-Term Remission After Nelarabine and Donor Lymphocyte Infusion in a Patient With T-ALL Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
Koruk K., Tiryaki T. O., ÖZBALAK M. M., MASTANZADE M., Arslan O., BEŞIŞIK S., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, 2024 (SCI-Expanded)
2024
202410. Identification of HLA alleles involved in immune thrombotic thrombocytopenic purpura patients from Turkey.
Kıkılı C. İ., Kıvanç D., Ortaboz D., Şentürk Çiftçi H., Özbalak M. M., Yenerel M. N., et al.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
, vol.35, no.6, pp.307-315, 2024 (SCI-Expanded, Scopus)
2023
202311. Sequencing novel agents in the treatment of classical hodgkin lymphoma.
Ferhanoglu B., Özbalak M. M.
Expert review of hematology
, 2023 (SCI-Expanded)
2023
202312. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
Atesoglu E. B., Gulbas Z., UZAY A., ÖZCAN M., ÖZKALEMKAŞ F., Dal M. S., et al.
HEMATOLOGICAL ONCOLOGY
, vol.41, no.4, pp.663-673, 2023 (SCI-Expanded)
2023
202313. CLL-079 The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia (CLL)
Seyithanoglu D., Nazligul E., Ozbalak M. M., Mastanzade M., Erdem S., Nalcaci M., et al.
CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA
, vol.23, pp.319-320, 2023 (SCI-Expanded)
2023
202314. The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia (CLL)
Seyithanoglu D., Nazligul E., ÖZBALAK M. M., MASTANZADE M., ERDEM S., NALÇACI M., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, 2023 (SCI-Expanded)
2023
202315. Independent risk factors for COVID-19-associated coagulopathy
Tor Y., Ozbalak M. M., Kalayoglu-Besisik S., Aksoy E., Cagatay A., Gul A., et al.
European Review for Medical and Pharmacological Sciences
, vol.27, no.16, pp.7851-7860, 2023 (SCI-Expanded, Scopus)
2022
202216. Salvage Intrapartum Splenectomy for the Treatment of Transfusion-refractory Anaemia in a ß-thalassemia Intermedia Patient.
Sivrikoz T. S., Ozbalak M., Ozmen A., Tukenmez M., Besisik S. K.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
, vol.32, no.10, pp.1344-1346, 2022 (SCI-Expanded)
2022
202217. High expression of OX-40, ICOS, and low expression PD-L1 of follicular helper and follicular cytotoxic T cells in chronic lymphocytic leukemia
Gelmez M. Y., Oktelik F. B., Çınar S., Ozbalak M. M., Ozluk O., Aktan M., et al.
JOURNAL OF HEMATOPATHOLOGY
, vol.15, no.3, pp.117-129, 2022 (SCI-Expanded, Scopus)
2022
202218. Dipyridamole does not have any additive effect on the prevention of COVID-19 coagulopathy.
Kalayoglu Besisik S., Ozbalak M. M., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., et al.
American journal of blood research
, vol.12, no.2, pp.54-59, 2022 (Peer-Reviewed Journal)
2022
202219. Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
Özbalak M. M., Güzel Mastanzade M., Özlük Ö., Tiryaki T. O., Erdem S., Özbalak E. P., et al.
TURKISH JOURNAL OF HEMATOLOGY
, vol.39, no.4, pp.254-261, 2022 (SCI-Expanded)
2021
202120. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series
Bayrak A. G., Daglar Aday A., Yavuz A. S., Nalcaci M., Ozbalak M. M., Cefle K., et al.
LEUKEMIA RESEARCH
, vol.111, 2021 (SCI-Expanded)
2021
202121. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
Akay O. M., Ozbalak M. M., Pehlivan M., Yildiz B., Uzay A., Yigenoglu T. N., et al.
Hematological oncology
, vol.39, no.4, pp.498-505, 2021 (SCI-Expanded)
2021
202122. Raman tweezers as an alternative diagnostic tool for paroxysmal nocturnal hemoglobinuria.
Soysal K. B., Parlatan S., Mastanzade M., Ozbalak M. M., Yenerel M. N., ÜNLÜ M. B., et al.
Analytical methods : advancing methods and applications
, vol.13, no.35, pp.3963-3969, 2021 (SCI-Expanded)
2021
202123. R-CHOP Chemotherapy with a Rituximab Biosimilar (Redditux®) for Patients with de novo Diffuse Large B-cell Lymphoma: First Preliminary Results of a Real-Life Single-Center Experience from Turkey
Özbalak M. M., Mastanzade M., Özlük Ö., Tiryaki T. O., Pınar Özbalak E., Yönal Hindilerden İ., et al.
İstanbul Kanuni Sultan Süleyman Tıp Dergisi , vol.13, no.3, pp.194-198, 2021 (Peer-Reviewed Journal)
2021
202124. Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study
Ozbalak M. M., Akay O. M., PEHLİVAN M., Yildiz B., UZAY A., Yigenoglu T. N., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, vol.21, 2021 (SCI-Expanded)
2021
202125. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY
Ozbalak M. M., Ozunal I. E., Berk S., ELVERDİ T., SALİHOĞLU A., EŞKAZAN A. E., et al.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI
, vol.84, no.2, pp.227-236, 2021 (ESCI)
2021
202126. Initial complete blood count score and predicting disease progression in COVID-19 patients.
Ozbalak M. M., Kalayoglu Besisik S., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., et al.
American journal of blood research
, vol.11, no.1, pp.77-83, 2021 (ESCI)
2021
202127. Initial complete blood count score and predicting disease progression in COVID-19 patients
Ozbalak M. M., Besisik S., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., et al.
AMERICAN JOURNAL OF BLOOD RESEARCH
, vol.11, no.1, pp.77-83, 2021 (ESCI)
2021
202128. Cytomegalovirus reactivation during adult acute lymphoblastic leukemia maintenance: do we underestimate (un)expected guest of pediatric approach?
Ozbalak M. M., Mastanzade M., GÜREL E., BEŞIŞIK S.
AMERICAN JOURNAL OF BLOOD RESEARCH
, vol.11, no.1, pp.118-122, 2021 (ESCI)
2020
202029. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
Bekoz H., ÖZBALAK M. M., Karadurmus N., PAYDAŞ S., Turker A., TOPTAŞ T., et al.
ANNALS OF HEMATOLOGY
, vol.99, no.11, pp.2565-2576, 2020 (SCI-Expanded)
2020
202030. Gıda Kaynaklı İmmünomodülatörler
Kohansal Koshksaray F., Özbalak M. M., Balkan İ. İ., Erten Yurdagül G.
Experimed
, vol.10, no.2, pp.97-111, 2020 (Peer-Reviewed Journal)
2020
202031. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.
Ozbalak M. M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., et al.
Annals of hematology
, vol.99, no.2, pp.301-307, 2020 (SCI-Expanded)
2020
202032. Retrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single Center 'Real-Life' Experience
Ozbalak M. M., MASTANZADE M., Ozluk O., TİRYAKİ T. O., Hindilerden I. Y., YENEREL M. N., et al.
MEDICAL JOURNAL OF BAKIRKOY
, vol.16, no.4, pp.392-398, 2020 (ESCI)
2020
202033. Bortezomib induced pulmonary toxicity: a case report and review of the literature
Saglam B., Kalyon H., Ozbalak M. M., Ornek S., Keske S., Tabak L., et al.
AMERICAN JOURNAL OF BLOOD RESEARCH
, vol.10, no.6, pp.407-415, 2020 (ESCI)
2018
201834. Venetoclax-Rituximab in Chronic Lymphocytic Leukemia
Ferhanoglu B., Ozturk E., ÖZBALAK M. M.
NEW ENGLAND JOURNAL OF MEDICINE
, vol.378, no.22, pp.2141-2143, 2018 (SCI-Expanded)
2017
201735. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F., et al.
Annals of oncology : official journal of the European Society for Medical Oncology
, vol.28, no.10, pp.2496-2502, 2017 (SCI-Expanded)
2017
201736. Inflammatory myofibroblastic tumor mimicking a relapse in a patient with Hodgkin's lymphoma: report of an unusual case and review of the literature.
Özbalak M. M., Torun E. S., ÖZDEMIRLI M., Uçar A. R., Akpınar T. S., Taşçıoğlu C., et al.
Clinical case reports
, vol.5, pp.945-949, 2017 (ESCI)
2017
201737. Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma
Falay O., Ozturk E., Bolukbasi Y., Gumus T., Ornek S., ÖZBALAK M. M., et al.
LEUKEMIA & LYMPHOMA
, vol.58, no.5, pp.1114-1122, 2017 (SCI-Expanded)
2017
201738. Bronchus Associated Lymphoid Tissue Lymphoma Presenting with Immunodeficiency and Multiple Pulmonary Nodules.
BOREKCI S., OZBALAK M. M., Ersen E., AKı H., CEM A. M., UMUT S.
Case reports in pulmonology
, vol.2017, pp.4804378, 2017 (Scopus)
2016
201639. Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
ÖZTÜRK E., ÖZBALAK M. M., Berk S., Erdoğan I., AVŞAR E., DOLGUN A., et al.
Leukemia & lymphoma
, vol.57, pp.1211-4, 2016 (SCI-Expanded)
2013
201340. Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.
Ozbalak M. M., TOKATLI I., Ozdemirli M., Tecimer T., Ar M. C., ORNEK S., et al.
European journal of haematology
, vol.91, no.5, pp.467-9, 2013 (SCI-Expanded)
2013
201341. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
Salihoglu A., Ozbalak M. M., Keskin D., Tecimer T., Soysal T., Ferhanoglu B.
Transplantation proceedings
, vol.45, no.7, pp.2845-8, 2013 (SCI-Expanded)
2013
201342. Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.
Ozbalak M. M., Ar M. C., Tuzuner N., Salihoglu A., Eskazan A. E., Ongoren Aydin S., et al.
ISRN hematology
, vol.2013, pp.908191, 2013 (Peer-Reviewed Journal)
2012
201243. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
Ozbalak M. M., Cetiner M., Bekoz H., Atesoglu E. B., Ar C., Salihoglu A., et al.
Hematological oncology
, vol.30, no.2, pp.76-81, 2012 (SCI-Expanded)
2009
200944. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases.
Ar M. C., Ozbalak M. M., Tuzuner N., Bekoz H., Ozer O., Ugurlu K., et al.
Transplantation proceedings
, vol.41, no.5, pp.1648-53, 2009 (SCI-Expanded)
2007
200745. Primary cutaneous T-cell lymphomas other than mycosis fungoides and primary cutaneous CD30(+) lymphoproliferative disorders
Ozbalak M. M., Demirkesen C., Oguz O., Onsun N., Tuzuner N.
VIRCHOWS ARCHIV
, vol.451, no.2, pp.456, 2007 (SCI-Expanded)
2007
200746. Prognostic significance of micro vessel density in diffuse large B cell lymphomas
Soer M., Ozbalak M. M., Senocak M., Soysal T., Ferhanoglu B., Molinas N., et al.
VIRCHOWS ARCHIV
, vol.451, no.2, pp.357-358, 2007 (SCI-Expanded)
Papers Presented at Peer-Reviewed Scientific Conferences
2025
20251. Yüksek Riskli Hematoloji Hastasında QT Uzaması ve Ekstrapiramidal Etkiler Açısından İlaç Etkileşimlerinin Değerlendirmesi ve Yönetimi
Arı A., Erdal M., Usta T., Özbalak M. M., Yönal Hindilerden İ., Alp Yıldırım F. İ., et al.
Marmara Üniversitesi Eczacılık Fakültesi Ulusal Eczacılık Kongresi, İstanbul, Turkey, 8 - 10 May 2025, pp.207-208, (Summary Text)
2025
20252. Chimerism Monitoring with Next- GenerationSequencing: Identification of Microchimerism BeyondSTR
Ögret Y., Çınar Ç., Özbalak M. M., Yönal Hindilerden İ., Oğuz F.
38th EFI Conference Immunogenetics , Praha, Czech Republic, 14 - 17 May 2025, pp.46-47, (Summary Text)
2025
20253. The Silent Threat of Secondary Malignancies in Multiple Myeloma Patients: A Cohort Study from Turkey in the Era of New Drugs
Mastanzade M., Taha F. J., Hasanzade U., İnan N. Y., Zeynallı B., Ören Çelik M. M., et al.
The 11th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy), Paris, France, 15 May 2025, (Summary Text)
2024
20244. A Single-Center Real-Life Experience with First-Line Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (DARA-VCD) in AL Amyloidosis
MASTANZADE M., ÖREN ÇELİK M. M., ERDEM S., ÖZBALAK M. M., YÖNAL HİNDİLERDEN İ., YENEREL M. N., et al.
Hematoloji Uzmanlık Derneği 18. Ulusal Kongresi, Antalya, Turkey, 21 - 24 November 2024, vol.46, pp.26-27, (Summary Text)
2024
20245. Akut Miyeloid Lösemide İzositrat Dehidrogenaz 1 (IDH1) Gen Mutasyonu Sıklığı ve Klinik: Tek Merkez Deneyimi
ÇATMA Y., ERDEM S., ADAY A., MASTANZADE M., ÖZBALAK M. M., YÖNAL HİNDİLERDEN İ., et al.
50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October 2024, pp.228, (Summary Text)
2024
20246. AL Amiloidozda Karaciğer Tutulumunun Sessiz İzleri: Fibroscan Yol Gösterir mi?
MASTANZADE M., DAĞCI G., ÖREN ÇELİK M. M., ERDEM S., ÇAVUŞ B., SAKCI E., et al.
50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October 2024, pp.185, (Summary Text)
2022
20227. Multipl miyelom dışı plazma hücre hastalıklarında kök hücre desteği ile yüksek doz kemoterapi deneyimi
TİRYAKİ T. O., YÖNAL HİNDİLERDEN İ., ERDEM S., MASTANZADE M., ÖZBALAK M. M., OLUK B., et al.
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.196-197, (Summary Text)
2022
20228. Büyük granüllü lenfosit artışı olan olguların tanısında immünfenotiplemenin rolü: Tek merkez deneyimi
NAZLIGÜL SERT E., TİRYAKİ T. O., ÖZBALAK M. M., MASTANZADE M., ÖZLÜK D. Ö., ERDEM S., et al.
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.199-200, (Summary Text)
2022
20229. Kronik lenfositer lösemi olgularının tanı sırasındaki T lenfosit alt gruplarının prognoz üzerine etkisi
SEYİTHANOĞLU D., NAZLIGÜL SERT E., ERDEM S., ÖZBALAK M. M., MASTANZADE M., ÖZLÜK D. Ö., et al.
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.145-146, (Summary Text)
2022
202210. Red cell alloimmunization in multi-transfused Turkish patients with hematologic disorders
Öztaşkın S., Yanaşık M., Özbalak M. M., Güzel Mastanzade M., Özlük Ö., Tiryaki T. O., et al.
EHA 2022 Hybrid Congress, Vienna, Austria, 9 - 17 June 2022, pp.2844, (Summary Text)
2021
202111. Relationship between HLA and COVID-19 in unrelated bone marrow donors
Erol A., D. Öğret Y., Kıvanç D., Süleymanoğlu M., Özbalak M. M., Beşışık B., et al.
Hacettepe Acta Medica- XVII. Congress of Medical Biology and Genetics, 28 - 31 October 2021, vol.52, pp.407-408, (Summary Text)
2021
202112. Kemik iliği bağışçılarında HLA ve COVID-19 ilişkisi
EROL A., Öğret Y., KIVANÇ D., SÜLEYMANOĞLU M., ÖZBALAK M. M., Beşışık B., et al.
XVII.Tıbbi Biyoloji ve Genetik Kongresi, 28 October 2021, vol.52, pp.407-408, (Summary Text)
2021
202113. ASPARAGINASE INDUCED SINUS VEIN THROMBOSIS IN AN ADULT YOUNG ALL PATIENT
OLUK B., KUBİLAY D. Ö., ÖZBALAK M. M., ERDEM S., BEŞIŞIK S.
XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.77, (Summary Text)
2021
202114. WHAT HAVE WE EXPERIENCED WITH COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISORDERS?
ERDEM S., MASTANZADE M., ÖZBALAK M. M., KUBİLAY D. Ö., TİRYAKİ T. O., OLUK B., et al.
XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.96, (Summary Text)
2021
202115. Yeni tanı DBBHL’de biyobenzer rituksimab (Redditux) içeren R-CHOP rejimi sonuçları: Tek merkez gerçek yaşam deneyimi
ÖZBALAK M. M., MASTANZADE M., KUBİLAY D. Ö., TİRYAKİ T. O., ERDEM S., Pınar Özbalak E., et al.
47. Ulusal Hematoloji Kongresi, Antalya, Turkey, 04 November 2021, (Full Text)
2021
202116. R-CHOP Chemotherapy Including Biosimilar Rituximab (Redditux) for De-Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single Center Experience
Özbalak M. M., Mastanzade M., Özlük Ö., Tiryaki T. O., Erdem S., Özbalak E. P., et al.
63rd ASH Annual Meeting and Exposition, Georgia, United States Of America, 11 - 14 December 2021, pp.4585, (Summary Text)
2021
202117. A Case of Congenital Afibrinogenemia with Two Successful Spontaneous Delivery after Recurrent Pregnancy Losses
Mastanzade M., Özbalak M. M., Beşışık S.
ISTH 2021 Congress, Pennsylvania, United States Of America, 17 - 21 July 2021, no.5, pp.312, (Summary Text)
2021
202118. Increased activity of follicular helper T and cytotoxic T cellsin chronic lymphocytic leukemia
Gelmez M. Y., Öktelik F. B., Çınar S., Özbalak M. M., Deniz G.
6th European Congress of Immunology (ECI 2021), Belgrade, Serbia, 1 September - 04 October 2021, pp.1, (Summary Text)
2021
202119. Increased activity of follicular helper T and follicular cytotoxic T cells in Chronic Lymphocytic Leukemia
Gelmez M. Y., Öktelik F. B., Çınar S., Özbalak M. M., Özlük Ö., Deniz G., et al.
6th European Congress of Immunology, Belgrade, Serbia, 1 - 04 September 2021, pp.245, (Summary Text)
2021
202120. Dual-Beam optical Manipulation of Red blood cells for the investigation of paroxysmal nocturnal hemoglobinuria
Parlatan U., Soysal K. B., Parlatan S., Mastanzade M., Ozbalak M. M., Yenerel M. N., et al.
Optical Manipulation and Its Applications, OMA 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021, (Full Text)
2021
202121. A raman tweezer study with single red blood cells for the diagnosis of paroxysmal nocturnal hemoglobinuria
Parlatan S., Parlatan U., Soysal K. B., Mastanzade M., Ozbalak M. M., Yenerel M. N., et al.
Optical Molecular Probes, Imaging and Drug Delivery, OMP 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021, (Full Text)
2020
202022. BAŞVURU ANI TAM KAN SAYIMI PUANLAMASININ COVID-19 HASTALARINDA İLERLEYİCİ HASTALIĞI GÖSTERMEDE ROLÜ
ÖZBALAK M. M., BEŞIŞIK S., TOR Y. B., MEDETALİBEYOĞLU A., KÖSE M., Şenkal N., et al.
46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, (Summary Text)
2020
202023. Prognostic value of pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratio in diffuse large B-cell lymphoma: a single-center experience
Dağcı G., Mastanzade M., Özbalak M. M., Kubilay D. Ö., Tiryaki T. O., Yönal Hindilerden İ., et al.
XIth Eurasian Hematology Oncology Congress, İstanbul, Turkey, 21 - 24 October 2020, no.42, pp.48-49, (Summary Text)
2020
202024. FUSARİUM SPP İLE SİNOPULMONER İNFEKSİYON: HEMATOLOJİK MALİGNİTELERDE İKİNCİ SIKLIKTA KÜF MANTARI İNFEKSİYONU
ÖZLÜK SEVEN Ö., OLUK B., ÖZBALAK M. M., SOLTANOVA L., ALTUNOK D., YILMAZ E., et al.
46. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 28 - 31 October 2020, pp.177-178, (Full Text)
2020
202025. Dipyridamole Added to Anticoagulant Prophylaxis: Decline in Poor Outcome of Clinically Severe Ill COVID-2019 Patients
BEŞIŞIK S., ÖZBALAK M. M., TOR Y. B., MEDETALİBEYOĞLU A., KÖSE M., Şenkal N., et al.
International Society on Thrombosis and Hemostasis Annual Congress 2020, 12 - 14 July 2020, (Summary Text)
2019
201926. A relapsed refractory CD30 positive cutaneous anaplastic large cell lymphoma with large B-cell transformation responding to brentuximab vedotin after multiple lines of treatment.
Erdem S., Özbalak M. M., Baykal C., Kalayoğlu Beşışık S.
Xth International Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, pp.560, (Summary Text)
2019
201927. A retrospective analysis of peripheral T-cell lymphoma patients: single-center 'real-life' experience
Ozbalak M. M., Besisik S., Mastanzade M., Ozluk O., Ozmen A., Hindilerden I. Y., et al.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85, (Summary Text)
2019
201928. Role of [Ga-68]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma; comparison to [F-18]-FDG-PET/CT
Tiryaki T. O., Kuyumcu S., Has-Simsek D., Ozbalak M. M., Ozluk D., Unal S., et al.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85, (Summary Text)
2019
201929. Role of [68Ga]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma comparison to [18F]-FDG-PET/CT
TİRYAKİ T. O., KUYUMCU S., HAS ŞİMŞEK D., ÖZBALAK M. M., KUBİLAY D. Ö., ÜNAL S. N., et al.
Xth International Eurasian Hematology-Oncology Congress, İstanbul, Turkey, 8 - 12 October 2019, vol.85, (Summary Text)
2019
201930. A relapsed refractory CD30 positive cutaneous anaplastic large cell lymphoma with large B-cell transformation responding to brentuximab vedotin after multiple lines of treatment
Erdem S., Ozbalak M. M., Baykal C., Besisik S.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85, (Summary Text)
2017
201731. Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience
Ferhanoglu A. B., ÖZBALAK M. M., SALİHOĞLU A., Soysal T., Karadogan I., Paydas S., et al.
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130, (Summary Text)
2017
201732. NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
Ferhanoglu B., Bekoz H., Karadurmus N., Paydas S., Gulbas Z., Turker A., et al.
22nd Congress of the European-Hematology-Association, Madrid, Spain, 22 - 25 June 2017, vol.102, pp.84-85, (Summary Text)
2016
201633. IS FDG-PET THE MOST SENSITIVE TOOL TO DIAGNOSE BLEOMYCIN INDUCED PNEUMONITIS IN HODGKIN'S LYMPHOMA?
Ozturk E., Falay O., Bolukbasi Y., Gumu T., Ornek S., ÖZBALAK M. M., et al.
10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22 - 25 October 2016, vol.101, pp.43, (Summary Text)
2012
201234. The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.
Ozturk M., Ozaydin S., Oyan B., Ozbalak M. M., Arpaci F., Paydas S., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text)